Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$14.35
▼ $0.19 (-1.3%)
Market data updated: 09/19 03:22 PM
News analyzed: 09/19/2026
Market Cap
$909.20M
Day Range
$14.29 - $14.51
52-Week Range
$12.72 - $16.74
Beta
—
Next Earnings
03.11.2026
Support
$14.29
Resistance
$15.67
INMD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-5.4% (1Y)
🟡 Moderate
Strengths: 2/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 1.6% of price
Risk
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.40 (3y annualized return -24.8% / max drawdown 62.2%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
35
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
26
Risk
50
Sentiment
50
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent coverage of InMode Ltd. has centered on its product innovation and steady financial performance. In early September the company unveiled Morpheus8 Cool, an upgraded RF microneedling system offering greater comfort and precision on its new Morpheus8MAX platform. August reports showed second‑quarter 2026 GAAP revenue of $95.6 million, flat year‑over‑year but with an earnings‑per‑share beat, while the stock slipped modestly. A separate legal update noted a court denial of an injunction request against a Steel Partners affiliate, with InMode awarded costs. The headlines also place InMode within a broader, rapidly expanding aesthetic‑medicine market driven by weight‑loss drug trends.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about InMode Ltd.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 6 vs. 6 out of the last 20 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
50
Psychology
92
Fundamentals
—
Technical
26
Valuation
—
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
+7%
Market Narrative
39
Fundamental Reality
50
Narrative Gap
-11
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant anchoring behavior suggests traders are fixating on the 1.1% proximity to support, likely treating it as a critical threshold. Herding is present but muted, as INMD lags peers, indicating selective participation rather than blind following. The narrative gap (-9) hints at a disconnect between market sentiment (41) and objective reality (50), possibly amplifying anchoring as traders weigh recent price action over fundamentals. The key question is whether the stock’s marginal support hold will reinforce anchoring or if a break could trigger a reassessment of the reference point.
Updated: 09/09/2026, 01:32 PM
What could change this?
👥 What the crowd believes
"Q2 revenue of $95.6M matches estimates, EPS beats at $0.35; shares slip 2.5% as growth stays flat."
"InMode lowers FY2026 Adj EPS guidance from $1.33-$1.38 to $1.29-$1.34 vs $1.34 analyst estimate."
"Haifa District Court denied Steel Partners affiliate's request for temporary injunctive relief in its entirety."
"INmune Bio receives ~$4.2M development cash rebate from Australia."
📈 11D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 100/100
🔴 Weakest match
Jesse Livermore — 28/100
🗣️ Why do they disagree?
The methodologies for INMD split sharply between those emphasizing patience, valuation, and cycle positioning and those lacking sufficient data or signaling caution. Charles Mackay’s high score suggests no obvious speculative frenzy, while Morgan Housel and Samuel Armstrong Nelson see it as a steady, long-term opportunity—either as a quiet compounder or a cyclically favorable buy. Even Howard Marks and Gerald Loeb find the risk-reward balance acceptable, though less enthusiastically. In contrast, the middle-tier approaches—like Jack Schwager’s neutral stance or the efficient-market skeptics—struggle to justify a clear edge over passive investing. Meanwhile, the lowest scores (Livermore’s negative trend signal and Smith’s lack of dividend/growth data) reflect either a technical breakdown or fundamental gaps, while the majority of traditional value/growth frameworks (Graham, Fisher, Lynch) simply lack the data to form a definitive opinion. The divide underscores whether INMD’s appeal lies in its cyclical or patient-investor-friendly traits—or if it’s too murky for most systematic frameworks.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 96
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 80
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 71
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 70
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 63
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 52
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 28
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 6 positive, 8 neutral, 6 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
Yahoo · 9.9.2026
PR Newswire · 9.9.2026
Yahoo · 1.9.2026
CNW Group · 1.9.2026
Benzinga · 11.8.2026
SeekingAlpha · 8.8.2026
Associated Press · 5.8.2026
PR Newswire · 5.8.2026
Yahoo · 5.8.2026
ChartMill · 5.8.2026
Benzinga · 5.8.2026
Benzinga · 5.8.2026
Benzinga · 31.7.2026
Business Wire · 28.7.2026
Business Wire · 16.7.2026
MT Newswires · 13.7.2026
MT Newswires · 13.7.2026
MT Newswires · 13.7.2026
MT Newswires · 13.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for InMode Ltd. (INMD) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for INMD specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
INMD's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 1.6% of price; +5.2% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: Calmar: -0.40 (3y annualized return -24.8% / max drawdown 62.2%); Price is below the 50-day average; Price is below the 200-day average.
StockIQ has no recorded dividend payment history for INMD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 8 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Itzkovich Moshe | Grant/Award from Employer | 4.8.2026 | 14,000 | +14,000 | — |
| Itzkovich Moshe | Grant/Award from Employer | 4.8.2026 | 38,430 | +14,000 | — |
| Ron Hadar | Grant/Award from Employer | 30.7.2026 | 2,000 | +2,000 | — |
| Kenneth Nadav | Grant/Award from Employer | 30.7.2026 | 2,000 | +2,000 | — |
| Nass Shlomo | Grant/Award from Employer | 30.7.2026 | 2,000 | +2,000 | — |
| Ron Hadar | Grant/Award from Employer | 30.7.2026 | 60,270 | +2,000 | — |
| Nass Shlomo | Grant/Award from Employer | 30.7.2026 | 2,000 | +2,000 | — |
| Kenneth Nadav | Grant/Award from Employer | 30.7.2026 | 5,000 | +2,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,348,306 shares short as of 2026-08-31 · vs. 2,333,509 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.9% of trading volume this week was short selling, vs. 52.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology